Mytilineos eyes potential dual listing in London April 25, 2024 Greek energy giant Mytilineos has said it is eyeing a potential secondary listing in London before the end of next year.
Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York April 25, 2024 Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
Schroders posts rise in assets as it looks to rebound from ‘challenging’ year April 25, 2024 Schroders has reported an uptick in assets under management during the first three months of this year as it looks to rebound from a challenging 2023.
Hikma: Pharma giant starts year strong as new product sales surge in key markets April 25, 2024 In 2023, the group became the second-largest pharmaceutical company in Middle East and North Africa by sales.
Engineering group Weir sees bright future for mining as 2024 orders tick up April 25, 2024 Weir Group said it is on track to reduce company costs by £60m and grow operating margin to 20 per cent by 2026.
Sainsbury’s predicts profit to exceed £1bn as Aldi price-matching pays off April 25, 2024 Supermarket Sainsbury’s expects profits to exceed £1bn this year as it continues to win shoppers with loyalty card and Aldi price matching schemes.
Drax trading on track for the year as it awaits Westminster’s carbon capture sign-off April 25, 2024 Drax awaits the green light from the government on a bridging mechanism for its carbon capture project
London Stock Exchange owner’s growth meets estimates as it leans into Microsoft data deal April 25, 2024 The London Stock Exchange Group (LSEG) has reported first-quarter growth in line with analysts' estimates as it plans to start releasing products from its tie-up with Microsoft in the coming months.
WPP expects to return to growth in second-half as AI tools ‘deployed at scale’ April 25, 2024 For the full year, the company said it expected to report like-for-like revenue growth less pass-through costs of zero to one per cent.
Astrazeneca’s revenue surges as pipeline investments pay off April 25, 2024 Pascal Soriot, chief executive officer of AstraZeneca, said: "Astrazeneca had a very strong start in 2024 with substantial total revenue growth of 19 per cent in the first quarter.